Glenmark and Bausch Health collaborate to commercialise Ryaltris nasal spray in Canada

On Monday, Glenmark pharma, a global integrated pharmaceutical company announced that it has entered into a licensing agreement with an affiliate of Bausch Health Companies Inc through its subsidiary Glenmark Specialty SA in Switzerland for the commercialisation of Glenmark’s innovative nasal spray, Ryaltris, which is under review by Health Canada. 

Under the ambit of the agreement, Glenmark will be responsible for regulatory approvals and the supply of Ryaltris™ for the Canadian market whereas Bausch Health would be responsible for commercialisation of Ryaltris™ in the Canadian market, following the regulatory approval. In addition to royalties and supply price from sales of Ryaltris™, Glenmark will receive an upfront payment, launch & sales‐based milestone payments. 

Currently, Ryaltris™ (Olopatadine Hydrochloride 665 mcg and Mometasone Furoate 25 mcg) is under review by Health Canada with a proposed indication for the treatment of seasonal allergic rhinitis in adults and children over 12 years of age. After approval in Canada, Ryaltris™ will offer a fixed‐dose combination of two different classes of medications in a convenient nasal spray presentation. Ryaltris™ marks Glenmark's first truly global brand launch to date in the portfolio of respiratory medicine. 

Glenmark Pharma is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).   

Despite the news, the share of Glenmark Pharmaceutical was trading at Rs 456.90, which is 0.32 per cent down on BSE.